27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and Alzheimer's disease (AD) share several neuropathophysiological mechanisms, including axonal injury, neuroinflammation, and abnormal protein aggregation, which may contribute to overlapping clinical manifestations. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Wildfire smoke exposure is increasing across the U.S., but the long-term neurological effects of smoke-specific fine particulate matter (PM 2.5 ) and its carbonaceous components remain uncertain. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher UGS coverage was associated with a lower risk of incident AD among older adults in urban South Korea. 4 key findings →
Design: cohort study Participants: 95,822 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders, yet the environmental drivers that accelerate its progression remain poorly defined. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Higher exposure to PM 2.5 was associated with cerebral arteriolosclerosis and atherosclerosis at death, consistent with the known vascular toxicity of this pollutant. 5 key findings →
Design: cohort study Participants: 909 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Exposure to the highest quintile of PM 2·5 (Rte:1·14, 95% CI:1·06-1·23), NO x (Rte:1·11, 95% CI:1·03-1·20) or NO 2 (Rte:1·08, 95% CI:0·99-1·16), compared to the lowest quintile, was associated with higher dementia risk. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Ambient air pollution has been associated with increased incidence of chronic disease and is estimated to contribute towards 4.2 million early deaths annually. 2 key findings →
Participants: 22,071 Evidence: low
Full summary, score breakdown and related studies → Original source
Direct medical and productivity-related costs associated with incident cases were estimated using a cost-of-illness (COI) framework. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Middle East and North Africa (MENA) region represents the area of greatest projected growth in instances of Alzheimer’s disease and related dementias (ADRDs) globally, yet, it remains virtually uncharacterized in health studies of aging and ADRDs. 4 key findings →
Participants: 3,552 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 1,288,359 women, 20,070 with AUD were matched to 100,339 controls. 3 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
The 2,885 participants had a mean age of 69.5 years. 4 key findings →
Design: longitudinal study Participants: 2,885 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuroticism, a personality trait characterized by the predisposition to experience intense and frequent negative emotions, has been associated with an increased risk of Alzheimer’s disease (AD). 5 key findings →
Participants: 1,277 Evidence: low
Full summary, score breakdown and related studies → Original source
INTRODUCTIONLittle is understood about the extent to which lifestyle factors can advance or delay the risk of developing dementia, and whether that is dependent on non-modifiable factors, e.g. sex and genetic susceptibility.METHODSAmong 224,516 UK Biobank participants aged ≥50 years at baseline, Cox regression examined the relations of apolipoprotein E gene (APOE) genotypes, and lifestyle with incident dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Vascular risk factors were associated with CSVD burden and progression, and WMH and PVS progression were further associated with cortical atrophy and cognitive decline, underscoring the interconnected contributions of vascular risk, CSVD, and neurodegeneration to cognitive aging and dementia risk. 5 key findings →
Design: cross-sectional Participants: 289 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
In a contemporary, diverse cohort, most established dementia risk algorithms had limited power in discriminating amyloid positivity, pTau-217 positivity, and current cognitive status despite acceptable calibration. 3 key findings →
Participants: 603 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In SPRINT, intensive vs standard SBP control yielded a significantly larger 4-year absolute risk reduction in dementia among APOE ε4 carriers (−1.7%) than non-carriers (0.2%; P-interaction = .045); the relative-scale interactions were directionally consistent but not significant. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Lifetime TBI exposure is associated with increased likelihood and long-term risk of psychiatric disorders in individuals with dementia, stroke, and Parkinson’s disease, with mood disorders being the most consistent outcome across conditions. 4 key findings →
Participants: 502,154 Evidence: moderate
Full summary, score breakdown and related studies → Original source
No association between cadmium exposure and dementia incidence was observed. 2 key findings →
Design: longitudinal study Participants: 6,122 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Both classes act on neuronal calcium signaling, raising the question of whether their combined use is associated with greater cognitive risk than gabapentin alone. 5 key findings →
Design: cohort study Participants: 33,791 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with peripheral artery disease (PAD), chronic limb-threatening ischemia (CLTI), and/or diabetic foot ulcer (DFU) are at increased risk for limb loss and death. 3 key findings →
Participants: 178,995 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years. 5 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source
Among 9,386 propensity score-matched pairs of ND patients and controls, covariates were well balanced. 5 key findings →
Design: retrospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia risk may be increased among people with HIV with certain cancers, including AIDS-defining cancers. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The prevalence of dementia and Parkinson’s disease in Russia varies widely depending on diagnostic method, age group, and study design. 2 key findings →
Design: meta-analysis Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
10 of the 3,247 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →